Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | TP53 | P04637 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3758966 | 0.93 | KDM4E (0.67) | LMNAKDM4EALDH1A1HSD17B10KMT2A | |
| SCHEMBL13058212 | 0.88 | TP53 (0.56) | LMNAKDM4EALDH1A1HSD17B10KMT2A | |
| SCHEMBL3757655 | 0.88 | LMNA (0.62) | LMNAKDM4EALDH1A1HSD17B10KMT2A | |
| SCHEMBL13058183 | 0.86 | EGFR (0.55) | LMNAKDM4EALDH1A1HSD17B10KMT2A | |
| SCHEMBL3756483 | 0.86 | TP53 (0.54) | LMNAKDM4EALDH1A1HSD17B10KMT2A | |
| SCHEMBL13058202 | 0.86 | TP53 (0.53) | LMNAKDM4EALDH1A1HSD17B10KMT2A | |
| SCHEMBL3763448 | 0.85 | MAPT (0.61) | LMNAKDM4EALDH1A1HSD17B10KMT2A | |
| SCHEMBL13747890 | 0.83 | TP53 (0.51) | LMNAKDM4EALDH1A1HSD17B10KMT2A | |
| SCHEMBL3761948 | 0.82 | KDM4E (0.56) | LMNAKDM4EALDH1A1HSD17B10KMT2A | |
| SCHEMBL3767092 | 0.81 | KDM4E (0.72) | LMNAKDM4EALDH1A1HSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349847-B2 | Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents | KONAKANCHI DURGA PRASAD (IN) | 2013-01-08 | — | — | US | claimed |
| US-8349847-B2 | Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents | KONAKANCHI DURGA PRASAD (IN) | 2013-01-08 | — | — | US | disclosed |
| US-8349847-B2 | Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents | KONAKANCHI DURGA PRASAD (IN) | 2013-01-08 | — | — | US | disclosed |
| US-20100298351-A1 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2010-11-25 | — | — | US | disclosed |
| US-20100298351-A1 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2010-11-25 | — | — | US | disclosed |
| WO-2009098715-A2 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI -CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298351-A1 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS | DPYD, TYMP, TYMS | LMNA 4335/4885KDM4E 1866/4885ALDH1A1 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.